Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31416614 | 0.84 | ALDH1A1 (0.52) | ENPP2CA2CA1MAPTTSHR | |
| SCHEMBL23114 | 0.81 | ENPP2 (0.52) | ENPP2CA2CA1TSHRTUBB4A | |
| SCHEMBL25173988 | 0.79 | ENPP2 (0.54) | ENPP2CA2CA1TUBB4ATUBB | |
| SCHEMBL23051 | 0.78 | ENPP2 (0.48) | ENPP2CA2CA1MAPTTUBB4A | |
| SCHEMBL29956693 | 0.78 | MAOB (0.57) | ENPP2CA2CA1TSHRALDH1A1 | |
| SCHEMBL11322 | 0.78 | MAOB (0.57) | ENPP2CA2CA1TSHRALDH1A1 | |
| SCHEMBL1018126 | 0.76 | ENPP2 (0.49) | ENPP2CA2CA1MAPTTSHR | |
| SCHEMBL22471 | 0.76 | ENPP2 (0.47) | ENPP2CA2CA1TUBB4ATUBB | |
| SCHEMBL723787 | 0.76 | ALDH1A1 (0.55) | ENPP2CA2CA1TSHRTUBB4A | |
| SCHEMBL29427068 | 0.76 | ENPP2 (0.49) | ENPP2CA2CA1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117088884-A | Imidazopyridazine derivatives as GABAA receptor modulators, pharmaceutical compositions and uses | 上海赛默罗德生物科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2020030924-A1 | THIAZOLEUREAS AS ANTICANCER AGENTS | ARTIOS PHARMA LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020030924-A1 | THIAZOLEUREAS AS ANTICANCER AGENTS | ARTIOS PHARMA LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| US-9505772-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-29 | — | — | US | disclosed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20150111894-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-23 | — | — | US | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| EP-2848622-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-8951993-B2 | Phosphorus containing compounds as protein kinase inhibitors | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2015-02-10 | — | — | US | disclosed |
| US-8574546-B2 | Substituted aryl-fluoroborates as imaging agents | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-11-05 | — | — | US | disclosed |
| US-8574546-B2 | Substituted aryl-fluoroborates as imaging agents | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-11-05 | — | — | US | disclosed |
| US-20120220551-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012116050-A2 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2012-08-30 | — | — | WO | disclosed |
| US-20100254903-A1 | Substituted Aryl-Fluoroborates as Imaging Agents | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-10-07 | — | — | US | disclosed |
| US-20100254903-A1 | Substituted Aryl-Fluoroborates as Imaging Agents | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-10-07 | — | — | US | disclosed |
| WO-2009012596-A1 | SUBSTITUTED ARYL-FLUOROBORATES AS IMAGING AGENTS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220551-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | PPM1A, PPM1G, PPM1B | ENPP2 312/4885CA2 380/4885CA1 1574/4885 |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | ENPP2 631/4885CA2 2991/4885CA1 4595/4885 |
| US-20100254903-A1 | Substituted Aryl-Fluoroborates as Imaging Agents | SIGMAR1, AP3S1, SLC1A5 | ENPP2 2529/4885CA2 2794/4885CA1 2857/4885 |
| US-20150111894-A1 | AROMATIC RING COMPOUND | MC1R, MC4R, TYR | ENPP2 1761/4885CA2 2429/4885CA1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.